Avalyn Pharma(AVLN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AVLN Avalyn Pharma

盘后交易 07-22 19:52:06 EDT

28.72

-0.31

-1.07%

盘后28.73

+0.01+0.03%

19:34 EDT

最高30.45	最低28.25	成交量29.40万
今开28.66	昨收29.03	日振幅7.58%
总市值12.73亿	流通市值4.79亿	总股本4,433万
成交额859.60万	换手率1.76%	流通股本1,667万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AVLN","market":"US","secType":"STK","nameCN":"Avalyn Pharma","latestPrice":28.72,"timestamp":1784750400000,"preClose":29.03,"halted":0,"volume":293985,"hourTrading":{"tag":"盘后","latestPrice":28.73,"preClose":28.72,"latestTime":"19:34 EDT","volume":2171,"amount":62340.98143,"timestamp":1784763247874,"change":0.01,"changeRate":0.000348,"amplitude":0.002786},"delay":0,"changeRate":-0.010678608336204005,"floatShares":16666700,"shares":44333095,"eps":-2.133,"marketStatus":"盘后交易","change":-0.31,"latestTime":"07-22 19:52:06 EDT","open":28.66,"high":30.45,"low":28.25,"amount":8595976.75938,"amplitude":0.075784,"askPrice":30,"askSize":1,"bidPrice":26.5,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-2.133,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1784764800000},"marketStatusCode":4,"adr":0,"listingDate":1777521600000,"exchange":"NASDAQ","adjPreClose":29.03,"postHourTrading":{"tag":"盘后","latestPrice":28.73,"preClose":28.72,"latestTime":"19:34 EDT","volume":2171,"amount":62340.98143,"timestamp":1784763247874,"change":0.01,"changeRate":0.000348,"amplitude":0.002786},"volumeRatio":1.05818},"requestUrl":"/m/hq/s/AVLN","defaultTab":"news","newsList":[{"id":"1150445147","title":"Avalyn完成AP01（吸入性吡非尼酮）针对进展性肺纤维化患者的2b期Mist试验目标入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1150445147","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150445147?lang=zh_cn&edition=full","pubTime":"2026-06-17 20:01","pubTimestamp":1781697684,"startTime":"0","endTime":"0","summary":"Avalyn Pharma宣布，其针对进展性肺纤维化患者研发的药物AP01（吸入性吡非尼酮）的2b期Mist临床试验，现已完成目标患者入组工作。这一关键里程碑标志着该试验已进入新的数据收集与分析阶段，为评估该吸入式疗法的有效性与安全性奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVLN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199282092","title":"Avalyn Pharma 将公布AP01（吸入性吡非尼酮）治疗肺纤维化的更多长期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1199282092","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199282092?lang=zh_cn&edition=full","pubTime":"2026-05-21 20:01","pubTimestamp":1779364877,"startTime":"0","endTime":"0","summary":"Avalyn Pharma宣布，关于其吸入性吡非尼酮（AP01）用于治疗肺纤维化的更多长期研究数据，将于2026年欧洲风湿病联盟大会上公布。这些数据有望进一步验证该疗法的长期疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVLN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197256686","title":"异动解读 | Avalyn Pharma IPO首日盘中大涨44.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=1197256686","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197256686?lang=zh_cn&edition=full","pubTime":"2026-05-01 01:26","pubTimestamp":1777570002,"startTime":"0","endTime":"0","summary":"Avalyn Pharma今日盘中大涨44.44%，引起了市场的广泛关注。消息面上，Avalyn Pharma是一家专注于开发治疗罕见呼吸系统疾病吸入式药物的生物技术公司，其于今日正式在纳斯达克全球精选市场挂牌交易。这两款药物分别为吡非尼酮和尼达尼布的吸入制剂，针对特发性肺纤维化等疾病，旨在提升疗效并减少副作用。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631507639","title":"肺纤维化生物技术公司Avalyn Pharma IPO定价18美元募资3亿，今晚登陆纳斯达克","url":"https://stock-news.laohu8.com/highlight/detail?id=2631507639","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631507639?lang=zh_cn&edition=full","pubTime":"2026-04-30 15:07","pubTimestamp":1777532834,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Avalyn Pharma是一家处于二期临床试验阶段的生物技术公司，专注于开发治疗罕见呼吸系统疾病的吸入式药物。Avalyn的股票预计于4月30日(周四)正式在纳斯达克全球精选市场挂牌交易。作为临床阶段的生物技术企业，Avalyn Pharma致力于研发针对罕见呼吸系统疾病的吸入式抗纤维化疗法。其核心候选药物AP01和AP02分别为吡非尼酮和尼达尼布的吸入制剂，旨在将已获批的抗纤维化药物直接递送至肺部，提升局部药物暴露量并减少全身性副作用。","market":"hk","thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437125.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSQ","TQQY","IYW","FTEC","BK1147","QQQY","NVIW.SI","QDTE","ONEQ","QQQM","TQQQ","MNQmain","QID","QQQA","BK4007","QQQE","AVLN","GPIQ","SQQQ","QLD","QYLG","QQQJ","QQQ","JEPQ"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1154944245","title":"Avalyn Pharma任命行业领袖Adam Golden与Frank Salisbury，强化领导团队以支持长期增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1154944245","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154944245?lang=zh_cn&edition=full","pubTime":"2026-04-27 20:28","pubTimestamp":1777292892,"startTime":"0","endTime":"0","summary":"生物制药公司Avalyn Pharma宣布两项关键高层任命，旨在加强其领导团队实力，为公司长期发展提供战略支持。公司正式任命Adam Golden和Frank Salisbury担任重要领导职务，两位行业资深人士的加入将助力Avalyn推进其创新疗法研发管线。此次人事变动彰显了Avalyn Pharma在呼吸疾病治疗领域持续扩张的决心。通过对领导团队的战略性补强，Avalyn进一步巩固了其在新药研发领域的竞争优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629818634","title":"肺纤维化生物技术公司Avalyn Pharma(AVLN.US)IPO定价16至18美元 拟募资2.01亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629818634","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629818634?lang=zh_cn&edition=full","pubTime":"2026-04-24 15:07","pubTimestamp":1777014466,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Avalyn Pharma是一家专注于开发用于治疗罕见呼吸系统疾病的吸入式药物的二期生物技术公司，于周四公布了其首次公开募股条款。作为一家临床阶段的生物技术公司，Avalyn Pharma致力于开发用于治疗罕见呼吸系统疾病的吸入式抗纤维化疗法。自 2011 年成立以来，Avalyn 已累计获得超过 3.8 亿美元的私募股权投资。Avalyn Pharma成立于2011年，计划在纳斯达克上市，股票代码为AVLN。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AVLN","UUP","IPOS","UDN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avalynpharma.com","stockEarnings":[{"period":"1week","weight":0.0265},{"period":"1month","weight":-0.0769},{"period":"3month","weight":0.6128},{"period":"ytd","weight":0.6128}],"compareEarnings":[{"period":"1week","weight":-0.0047},{"period":"1month","weight":0.0021},{"period":"3month","weight":0.0521},{"period":"6month","weight":0.0861},{"period":"1year","weight":0.1901},{"period":"ytd","weight":0.0973}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Avalyn Pharma Inc.于2011年5月27日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司，开发吸入药物以治疗罕见的呼吸道疾病，包括进行性肺纤维化、特发性肺纤维化和其他间质性肺部疾病。","exchange":"NASDAQ","name":"Avalyn Pharma","nameEN":"Avalyn Pharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avalyn Pharma(AVLN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Avalyn Pharma(AVLN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Avalyn Pharma,AVLN,Avalyn Pharma股票,Avalyn Pharma股票老虎,Avalyn Pharma股票老虎国际,Avalyn Pharma行情,Avalyn Pharma股票行情,Avalyn Pharma股价,Avalyn Pharma股市,Avalyn Pharma股票价格,Avalyn Pharma股票交易,Avalyn Pharma股票购买,Avalyn Pharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avalyn Pharma(AVLN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Avalyn Pharma(AVLN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}